ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2WHOAVe
via IFTTT